The Influence of Sex on Prognosis of Patients With Idiopathic Pulmonary Fibrosis in a Retrospective Cohort | Archivos de Bronconeumología
Subscribe to this journal
Advanced Search
Share
Subscribe
COVID-19
Metrics
Editorial Board
Publish in this journal
  • Instructions for authors
  • Submit an article
  • Ethics in publishing
  • Contact
Share
November 2017 The Influence of Sex on Prognosis of Patients With Idiopathic Pulmonary Fibrosis in...
    Archivos de Bronconeumología
    ISSN: 0300-2896

    Archivos de Bronconeumologia is a scientific journal that preferentially publishes prospective original research articles whose content is based upon results dealing with several aspects of respiratory diseases such as epidemiology, pathophysiology, clinics, surgery, and basic investigation. Other types of articles such as reviews, editorials, a few special articles of interest to the society and the editorial board, scientific letters, letters to the Editor, and clinical images are also published in the Journal. It is a monthly Journal that publishes a total of 12 issues and a few supplements, which contain articles belonging to the different sections.

    All the manuscripts received in the Journal are evaluated by the Editors and sent to expert peer-review while handled by the Editor and/or an Associate Editor from the team. The Journal is published monthly in English.

    Manuscripts will be submitted electronically using the following web site: https://www.editorialmanager.com/ARBR/, link which is also accessible through the main web page of Archivos de Bronconeumologia.

    Access to any published article, is possible through the Journal's web page as well as from PubMed, Science Direct, and other international databases. Furthermore, the Journal is also present in Twitter and Facebook. The Journal expresses the voice of the Spanish Respiratory Society of Pulmonology and Thoracic Surgery (SEPAR) as well as that of other scientific societies such as the Latin American Thoracic Society (ALAT) and the Iberian American Association of Thoracic Surgery (AICT).

    Authors are also welcome to submit their articles to the Journal's open access companion title, Open Respiratory Archives.

    See more

    Indexed in:

    Current Contents/Clinical Medicine, JCR SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, SCOPUS, IBECS

    See more

    Follow us:

    Subscribe:

    Impact factor

    The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

    © Clarivate Analytics, Journal Citation Reports 2021

    See more
    Impact factor 2020
    4.872
    Citescore

    CiteScore measures average citations received per document published.

    See more
    Citescore 2020
    1.7
    SJR

    SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

    See more
    SJR 2020
    0.302
    SNIP

    SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

    See more
    SNIP 2020
    0.379
    View more metrics
    Open Access Option
    Hide
    Journal Information
    Previous article | Next article
    Vol. 53. Issue 11.
    Pages 649-650 (November 2017)
    Lee este artículo en Español
    Share
    Share
    Print
    Download PDF
    More article options
    ePub
    Statistics
    Vol. 53. Issue 11.
    Pages 649-650 (November 2017)
    Scientific Letter
    DOI: 10.1016/j.arbr.2017.03.023
    Full text access
    The Influence of Sex on Prognosis of Patients With Idiopathic Pulmonary Fibrosis in a Retrospective Cohort
    Influencia del género en el pronóstico de pacientes con fibrosis pulmonar idiopática en una cohorte retrospectiva
    Visits
    ...
    Download PDF
    Fabián Matías Caro
    Corresponding author
    fabiancarodoc@gmail.com

    Corresponding author.
    , María Laura Alberti, Martín Eduardo Fernández, Francisco Paulin
    Consultorio multidisciplinario de enfermedades pulmonares intersticiales, Hospital de Rehabilitación Respiratoria «María Ferrer», Buenos Aires, Argentina
    This item has received
    ...
    Visits
    (Daily data update)
    Article information
    Full Text
    Bibliography
    Download PDF
    Statistics
    Tables (1)
    Table 1. Unadjusted and Adjusted HR for Time to Death or Transplantation in a Cohort of Patients with Idiopathic Pulmonary Fibrosis Between 2012 and 2015 (N=86).
    Full Text
    To the Editor,

    Idiopathic pulmonary fibrosis (IPF) is a disease that occurs more often in men, with a reported male:female ratio of between 1.6:1 and 2:1.1,2 Previous studies indicate that the course of IPF may be more benign in women, an observation which could be based on differences in gene expression.3–5 Given that these studies were conducted prior to the publication of the current diagnostic criteria, and without taking into account the variable of autoantibodies, patients with diagnoses other than IPF might have been included. We believed, then, that a new study comparing the progress of these patients according to gender could provide valuable information.

    For this reason, we decided to perform this retrospective cohort study in patients with a diagnosis of IPF (according to the 2011 ATS/ERS/JPS/ALAT)6 seen in a multidisciplinary clinic specializing in interstitial lung diseases (ILD). Patients were recruited between March 2012 and July 2015. The main study outcome variable was time from date of diagnosis to date of all-cause death or lung transplantation. The main study exposure variable was sex. The following variables were analyzed to avoid potential confusion between sex and the outcome variable: age, smoking, time of dyspnea in months, the development of acute exacerbations (defined according to current international recommendations),7 rheumatoid factor (RF) by nephelometry, and antinuclear antibodies (ANA) by indirect immunofluorescence. Other study variables included previous treatment with triple therapy (systemic corticosteroids, azathioprine, and N-acetylcisteine) before attending our clinic, and use of pirfenidone. Results were communicated according to the indications of the STROBE initiative.8

    Time of death or transplantation was estimated using Kaplan–Meier methods. The rates of events between the sexes at 18 months were studied using survival estimators and 95% confidence intervals, and compared using the log rank test. A multivariate Cox model was applied, using sex as the first independent variable. Variables that were significant in the univariate analysis and those considered clinically relevant were included. Both crude and adjusted HR and their 95% CI were reported. A P-value of <.05 was considered statistically significant.

    The study included 86 patients, of which 21 were women (24.4%). Mean (SD) age was 65.4 (9) years. When characteristics were compared by sex, the prevalence of smoking was higher among men (84.6% vs 59.1%, P<.01). No significant differences in age, baseline forced vital capacity (FVC%), time since onset of dyspnea, or percentage of patients with positive ANA or RF were found at diagnosis. No differences were observed in the time of administration or proportion of patients who received triple therapy prior to attending our clinic, nor in the percentage of patients who received pirfenidone or had an acute exacerbation. In the analysis of time to death or transplantation, overall all-cause mortality was 38.4% (33/86), 35.4% (23/65) in men, and 47.6% (10/21) in women. Median survival was 34.03 months in women and 36.06 months in men. Four patients received a lung transplant (3 men) and the indication for transplantation was established at the time of diagnosis. When survival at 18 months was compared by sex, no statistically significant differences were observed, with rates of 0.75 (95% CI, 0.61–0.85) in men and 0.71 (95% CI, 0.44–0.87) in women (P=.88). In the Cox univariate analysis (Table 1), treatment with pirfenidone was associated with longer survival, but this effect disappeared after adjusting for the remaining variables included. In the Cox multivariate analysis, the only variable that showed statistical significance was baseline FVC% (Table 1).

    Table 1.

    Unadjusted and Adjusted HR for Time to Death or Transplantation in a Cohort of Patients with Idiopathic Pulmonary Fibrosis Between 2012 and 2015 (N=86).

      Unadjusted HR (95% CI)  P-Value  Adjusted HR (95% CI)  P-Value 
    Sex  0.89 (0.42–1.89)  .78  1.08 (0.36–3.22)  .88 
    Age at diagnosis, years  0.99 (0.95–1.03)  .79  1.01 (0.96–1.07)  .48 
    Smoking habit  0.63 (0.29–1.32)  .22  1.15 (0.43–3.08)  .48 
    Baseline FVC%  0.96 (0.94–0.99)  .01  0.96 (0.92–0.99)  .01 
    Positive ANA or RF  0.87 (0.43–1.78)  .77  1.05 (0.44–2.48)  .90 
    Received pirfenidone  0.27 (0.10–0.73)  .01  0.37 (0.13–1.08)  .07 
    Received triple therapy  0.83 (0.36–1.9)  .66  0.52 (0.17–1.59)  .25 

    ANA: antinuclear antibody; FVC%: forced vital capacity as percentage; IPF: idiopathic pulmonary fibrosis; RF: rheumatoid factor; HR; hazard ratio; CI: confidence interval.

    In our study, we found no significant differences when the survival of patients with IPF was compared by sex. Treatment with pirfenidone was significantly associated with better survival in the univariate analysis, but this effect disappeared in the multivariate analysis, although it maintained a trend toward statistical significance. This may be explained by the fact that patients who received pirfenidone had baseline FVC≥50% predicted value. Our study has some limitations. It is a retrospective study conducted in a single center. Moreover, with the exception of ANA and RF, other antibodies were not routinely analyzed. However, all patients were evaluated by the clinical immunology department, which ruled out the presence of an autoimmune disease by additional tests and determination of specific antibodies (e.g., citrullinated peptide antibodies or myospecific antibodies), when necessary.9 Previous studies indicate that the female sex is associated with better survival in IPF, and was considered a factor for good prognosis in a score proposed by a group of researchers.4,10 However, these studies were performed using the ATS/ERS criteria from the year 2000. A recent study showed that of 60 patients who met diagnostic criteria in the year 2000, only 46 met the current diagnostic criteria,11 suggesting that approximately 25% of patients with IPF according to previous criteria could have had another IPD. This is of interest, given the differences in survival between IPF and other ILD.12 Chronic hypersensitivity pneumonitis may be confused with IPF, which is relevant, since it has a more benign disease course.11 Autoimmune diseases are more common in women13 and may present a pattern of usual interstitial pneumonia indistinguishable from IPF,14,15 and generally associated with better survival. We believe that including autoantibodies in a survival analysis according to sex in patients with IPF is of crucial importance. Our study has been the first to include this adjustment variable and to use current diagnostic criteria to analyze the relationship between sex and survival in patients with IPF. As the patients included in our study meet the current criteria of IPF, and were evaluated by a specialist multidisciplinary group, we believe that our results are valid and can be extrapolated to other populations. However, prospective studies are needed to confirm our results.

    References
    [1]
    G. Raghu, D. Weycker, J. Edelsberg, W.Z. Bradford, G. Oster.
    Incidence and prevalence of idiopathic pulmonary fibrosis.
    Am J Respir Crit Care Med, 174 (2006), pp. 810-816
    http://dx.doi.org/10.1164/rccm.200602-163OC | Medline
    [2]
    A. Xaubet, J. Ancochea, R. Blanquer, C. Monterod, F. Morelle, E. Rodríguez Becerra, et al.
    Diagnóstico y tratamiento de las enfermedades pulmonares intersticiales difusas.
    Arch Bronconeumol, 39 (2003), pp. 580-600
    http://dx.doi.org/10.1157/13054364 | Medline
    [3]
    D.M. Mannino, R.A. Etzel, R.G. Parrish.
    Pulmonary fibrosis deaths in the United States, 1979–1991. An analysis of multiple-cause mortality data.
    Am J Respir Crit Care Med, 153 (1996), pp. 1548-1552
    http://dx.doi.org/10.1164/ajrccm.153.5.8630600 | Medline
    [4]
    M.K. Han, S. Murray, C.D. Fell, K.R. Flaherty, G.B. Toews, J. Myers, et al.
    Sex differences in physiological progression of idiopathic pulmonary fibrosis.
    Eur Respir J Off J Eur Soc Clin Respir Physiol, 31 (2008), pp. 1183-1188
    http://dx.doi.org/10.1183/09031936.00165207
    [5]
    S.P. McGee, H. Zhang, W. Karmaus, T. Sabo-Attwood.
    Influence of sex and disease severity on gene expression profiles in individuals with idiopathic pulmonary fibrosis.
    Int J Mol Epidemiol Genet, 5 (2014), pp. 71-86
    Medline
    Available in: www.ijmeg.org
    [6]
    G. Raghu, H.R. Collard, J.J. Egan, F.J. Martinez, J. Behr, K.K. Brown, et al.
    An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management.
    Am J Respir Crit Care Med, 183 (2011), pp. 788-824
    http://dx.doi.org/10.1164/rccm.2009-040GL | Medline
    [7]
    H.R. Collard, C.J. Ryerson, T.J. Corte, G. Jenkins, Y. Kondoh, D.J. Lederer, et al.
    Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group Report.
    Am J Respir Crit Care Med, 194 (2016), pp. 265-275
    http://dx.doi.org/10.1164/rccm.201604-0801CI | Medline
    [8]
    E. Von Elm, D.G. Altman, M. Egger, S.J. Pocock, P.C. Gotzsche, J.P. Vandenbroucke.
    Directrices para comunicación de estudios observacionales.
    Gac Sanit, 22 (2008), pp. 144-150
    http://dx.doi.org/10.1371/journal.pmed.0040296 | Medline
    [9]
    Y. Yin, D. Liang, L. Zhao, Y. Li, W. Liu, Y. Ren, et al.
    Anti-cyclic citrullinated peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis.
    PLoS One, 9 (2014), pp. 1-6
    http://dx.doi.org/10.1371/journal.pone.0092449
    [10]
    B. Ley, C.J. Ryerson, E. Vittinghoff, J.H. Ryu, S. Tomassetti, J.S. Lee.
    A multidimensional index and staging system for idiopathic.
    Ann Intern Med, 156 (2013), pp. 684-691
    http://dx.doi.org/10.7326/0003-4819-156-10-201205150-00004 | Medline
    [11]
    F. Morell, A. Villar, M.-Á. Montero, X. Muñoz, T.V. Colby, S. Pipvath, et al.
    Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case–cohort study.
    Lancet Respir Med, 1 (2013), pp. 685-694
    http://dx.doi.org/10.1016/S2213-2600(13)70191-7 | Medline
    [12]
    B. Bradley, H.M. Branley, J.J. Egan, M.S. Greaves, D.M. Hansell, N.K. Harrison, et al.
    Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.
    Thorax, 63 Suppl. 5 (2008), pp. 1-58
    http://dx.doi.org/10.1136/thx.2008.101691 | Medline
    [13]
    T.J. Corte, S.J. Copley, S.R. Desai, C.J. Zappala, D.M. Hansell, A.G. Nicholson, et al.
    Significance of connective tissue disease features in idiopathic interstitial pneumonia.
    Eur Respir J, 39 (2012), pp. 661-668
    http://dx.doi.org/10.1183/09031936.00174910 | Medline
    [14]
    D. Assayag, B.M. Elicker, T.H. Urbania, T.V. Colby, B.H. Kang, J.H. Ryu, et al.
    Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.
    Radiology, 270 (2014), pp. 583-588
    http://dx.doi.org/10.1148/radiol.13130187 | Medline
    [15]
    W.A. Wuyts, A. Cavazza, G. Rossi, F. Bonella, N. Sverzellati, P. Spagnolo.
    Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?.
    Eur Respir Rev, 23 (2014), pp. 308-319
    http://dx.doi.org/10.1183/09059180.00004914 | Medline
    ☆

    Please cite this article as: Caro FM, Alberti ML, Fernández ME, Paulin F. Influencia del género en el pronóstico de pacientes con fibrosis pulmonar idiopática en una cohorte retrospectiva. Arch Bronconeumol. 2017;53:649–650.

    Copyright © 2017. SEPAR


    Subscribe to our newsletter

    Special content about COVID-19
    • Consensus on the management of the COPD patient in the COVID-19 setting: COPD Forum Working Group
    • Tuberculosis Reactivation After Severe SARS-COV-2 Pneumonia
    • The Impact of Altitude on Mortality Rates From COVID-19 in Mexico
    • [Translated article] Histology Study of Postmortem Lung Biopsies in Patients With Covid-19 Pneumonia
    See more
    Tools
    • Print
    • Send to a friend
    • Export reference
    • CrossMark
    • Mendeley
    • Statistics
    Recommended
    articles
    Influencia del género en el pronóstico de pacientes con...
    Arch Bronconeumol 2017;53:649-50
    Experiencia de la vida real con pirfenidona en la fibrosis...
    Arch Bronconeumol 2019;55:75-80
    Traducción al español y validación del cuestionario...
    Arch Bronconeumol 2018;54:68-73
    Sociedad Española de Neumología y Cirugía Torácica
    Asociación Latinoamericana del Tórax y Asociación Latinoamericanade Cirugía Torácica
    Publish in
    Archivos de Bronconeumología
    • Instructions for authors
    • Submit an article
    • Ethics in publishing
    • Contact
    Podcast
    Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable
    Your browser does not support the audio element.
    Graphical abstract
    Archivos de Bronconeumología is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
    www.publicationethics.org.
    Open Respiratory Archives
    Pulmonology

    Read

    • Articles in press
    • Current Issue
    • Most Often Read

    Archive

    • Archive
    • Supplements

    Publish in this journal

    • Instructions for authors
    • Submit an article
    • Ethics in publishing
    • Contact
    • Editorial Board

    Legal terms

    • Reproduction terms
    • Terms and conditions
    • Privacy policy
    • Advertising

    Subscribe

    • Subscribe to this journal
    • Email alerts
    • RSS

    Advertising

    • Contract
    Contact
    Editorial Board
    © Copyright 2022. Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Asociación Latinoamericana del Tórax (ALAT). Asociación Sudamericana de Cirugía Torácica (ASCT)

    Cookies are used by this site. To decline or learn more, visit our Cookies page.
    Elsevier España S.L.U. © 2022. Todos los derechos reservados
    Archivos de Bronconeumología
    • Current Issue
    • Articles in press
    • Archive
    • Supplements
    • Most Often Read
    • Editorial Board
    • Publish in this journal
      • Instructions for authors
      • Submit an article
      • Ethics in publishing
      • Contact

    Subscribe to our newsletter

    Article options
    • Léalo en español
    • Download PDF
    • Bibliography
    Tools
    • Print
    • Send to a friend
    • Export reference
    • CrossMark
    • Mendeley
    • Statistics

    Are you a health professional able to prescribe or dispense drugs?